(Reuters) -Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after ...

Novavax shares declined after a Wall Street Journal report that federal regulators are asking the company to complete an additional randomized clinical trial on its Covid-19 vaccine, according to ...

By Julie Steenhuysen CHICAGO (Reuters) -Thousands of Americans campaigning for the Novavax COVID-19 booster got some good ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

The company says its vaccine is on track for full approval, following delay. Novavax shares soared following the announcement ...

Novavax's COVID-19 vaccine could soon receive full approval from the U.S. Food and Drug Administration (FDA), the company ...

According to a statement that was released by Novavax on Wednesday, it appears that the Food and Drug Administration (FDA) of the United States of America will shortly give the COVID-19 vaccine its ...

On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...

Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full ...

The FDA is asking Novavax for a non-mandatory postmarketing commitment to produce additional clinical data for its ...

The FDA is considering the approval of the Novavax COVID-19 booster after delays amid controversy over its non-mRNA design.

A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say ...